Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 2Terminated 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 79Carcinoma, Non-Small-Cell Lung 71Prostatic Neoplasms 68Neoplasms 52Multiple Myeloma 46Lung Neoplasms 42Colorectal Neoplasms 37Melanoma 32Lymphoma, Non-Hodgkin 30Pancreatic Neoplasms 29Neoplasm Metastasis 29Lymphoma 28Leukemia, Myeloid, Acute 27Squamous Cell Carcinoma of Head and Neck 26Ovarian Neoplasms 26Carcinoma, Renal Cell 25Precursor Cell Lymphoblastic Leukemia-Lymphoma 22Leukemia, Lymphocytic, Chronic, B-Cell 22Endometrial Neoplasms 22Stomach Neoplasms 20Sarcoma 20Carcinoma, Hepatocellular 20Urinary Bladder Neoplasms 19Glioma 19Uterine Cervical Neoplasms 18Recurrence 18Rectal Neoplasms 18Lymphoma, Mantle-Cell 17Hematologic Neoplasms 17Head and Neck Neoplasms 17

Interventions

encorafenib 1Nivolumab 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Disease Progression × 30 days × Clear all
NCT04017650 2026-05-22

Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
38 enrolled
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡